This protocol applies to men with prostate cancer who have undergone radical prostatectomy and subsequently develop biochemical recurrence — defined as two consecutive PSA rises above an undetectable level — with no distant metastases confirmed on imaging.
A rising PSA following prostatectomy, in the absence of detectable distant metastases, indicates biochemical recurrence (BCR). The two-consecutive-PSA-rise criterion distinguishes true recurrence from transient fluctuations. Early recognition and prompt action at this stage are critical to preventing disease progression.
Management centres on early salvage radiotherapy directed at the prostate bed, given as soon as the decision to treat is made, combined with hormonal therapy. The complete regimen — including technique, dose thresholds, sequencing, and eligibility criteria — is detailed in the full structured protocol.